Company just reported earnings in which it increased revenue by 19.2%, EBITDA (Earnings before interest, taxes, depreciation, and amortization) was up 18.2% and adjusted net income increased 33%.
The company actually stated it saw 82% growth in their international business.
Now, the stock IS expensive. It's trading at a 15% premium to what it has historically traded at in terms of forward price to earnings over the last half decade.
There is a massive (and somewhat unwarranted) shift out of health and material companies right now due to vaccine news.
Although never impossible, I cannot see JWEL touching March lows.